NEW EFFICACY COMPARISON OF BENIDIPINE AND AZELNIDIPINE IN HYPERTENSION MANAGEMENT MONOTHERAPY OR ADD ON THERAPY

Sowndarriyaa M. G.*, Dr. P. Maheshwari, Dr. K. Karthickeyan, Dr. P. Shanmugasudaram

Hypertension is a major global health issue and a leading cause of heart-related problems and deaths. Among various treatment options, calcium channel blockers (CCBs) are very important. Benidipine and azelnidipine are two notable dihydropyridine agents. This review compares the pharmacodynamics, pharmacokinetics, and clinical effectiveness of benidipine and azelnidipine in both monotherapy and add-on therapy for managing hypertension. Benidipine is a triple L-, T-, and N-type calcium channel blocker. It provides long-lasting vasodilation and protects the kidneys, which makes it suitable for patients with existing kidney problems. On the other hand, azelnidipine is a selective L-type blocker. It offers a gradual and lasting reduction in blood pressure with fewer cardiovascular side effects like reflex tachycardia and swelling in the legs. The article highlights the specific advantages and drawbacks of each drug, emphasizing the need for personalized treatment based on patient characteristics. Evidence from clinical trials shows that both drugs are effective in reducing blood pressure, but the choice between them should consider comorbidities, tolerability, and treatment goals. Future research and real-world data may help clarify their roles in personalized hypertension management.